Clinical Trials
12 trialsNCT03691714 2026-06-01
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Completed
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT02087423 2026-04-06
ATLANTIC
AstraZeneca
Phase 2 Completed
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03238027 2024-05-17
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT03167619 2022-09-13
DORA
Duke University
Phase 2 Completed
NCT03162224 2022-08-25
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
Phase 1/2 Completed
NCT02777710 2021-09-05
MEDIPLEX
Centre Leon Berard
Phase 1 Completed
NCT02572687 2021-01-20
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
Phase 1 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02628132 2020-07-07
Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
King Faisal Specialist Hospital & Research Center
Phase 1/2 Completed
NCT02027961 2019-05-17
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune LLC
Phase 1 Completed